Sugi Predict

Sugi Predict / Compounds / Oleic Acid

Oleic Acid

Oleic Acid

SCHEMBL1230441

CCCCCCCC/C=C\CCCCCCCC(=O)O.Nc1nc2c(ncn2COCCO)c(=O)[nH]1

nearest known ligand 0.66

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PNP P00491 7/20 0.66
▸ HBB P68871 2/20 0.66
▸ BLM P54132 2/20 0.66
▸ USP2 O75604 1/20 0.66
▸ TSHR P16473 1/20 0.66
▸ EDNRA P25101 1/20 0.66
▸ HTR2A P28223 1/20 0.66
▸ RECQL P46063 1/20 0.66
▸ HSD17B10 Q99714 1/20 0.66
▸ HPRT1 P00492 6/20 0.54
▸ MEN1 O00255 2/20 0.53
▸ KMT2A Q03164 2/20 0.53
▸ MAPK1 P28482 1/20 0.52
▸ POLG P54098 1/20 0.49
▸ ALDH1A1 P00352 1/20 0.48
▸ LMNA P02545 1/20 0.48
▸ CYP3A4 P08684 1/20 0.48
▸ NFKB1 P19838 1/20 0.48
▸ VCP P55072 1/20 0.48
▸ SMN1; SMN2 Q16637 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Oleic Acid SCHEMBL1230444 1.00 PNP (0.66) PNPHBBBLMUSP2TSHR
Elaidic Acid SCHEMBL1230565 1.00 PNP (0.66) PNPHBBBLMUSP2TSHR
Palmitic Acid SCHEMBL18529399 0.95 PNP (0.73) PNPHBBBLMUSP2TSHR
Acyclovir SCHEMBL18529423 0.95 PNP (0.73) PNPHBBBLMUSP2TSHR
Acyclovir SCHEMBL689108 0.94 PNP (0.74) PNPHBBBLMUSP2TSHR
Acyclovir SCHEMBL2817609 0.91 PNP (0.76) PNPHBBBLMUSP2TSHR
SCHEMBL12671790 0.88 MEN1 (0.60) PNPHBBBLMUSP2TSHR
Acyclovir SCHEMBL20567690 0.87 PNP (0.79) PNPHBBBLMUSP2TSHR
Acyclovir SCHEMBL28448833 0.87 PNP (0.83) PNPHBBBLMUSP2TSHR
Acyclovir SCHEMBL9224824 0.85 PNP (0.86) PNPHBBBLMUSP2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230381323-A1 RELEASABLE CONJUGATES FISH & RICHARDSON PC 2023-11-30 — — US disclosed
US-11786599-B2 Releasable conjugates QUIAPEG PHARMACEUTICALS AB (SE) 2023-10-17 — — US disclosed
US-20230123784-A1 Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels ASCENDIS PHARMA A/S (DK) 2023-04-20 — — US disclosed
US-11559482-B2 Biodegradable polyethylene glycol based water-insoluble hydrogels ASCENDIS PHARMA A/S (DE) 2023-01-24 — — US disclosed
EP-4011396-A1 RELEASABLE CONJUGATES QuiaPEG Pharmaceuticals AB (SE) 2022-06-15 — — EP disclosed
EP-3592393-B1 RELEASABLE CONJUGATES QUIAPEG PHARMACEUTICALS AB (SE) 2021-12-01 — — EP disclosed
US-11116849-B2 Hydrogel-linked prodrugs releasing tagged drugs ASCENDIS PHARMA A/S (DK) 2021-09-14 — — US disclosed
EP-3782649-A1 BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS Ascendis Pharma A/S (DK) 2021-02-24 — — EP disclosed
EP-2459220-B1 BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS ASCENDIS PHARMA AS (DK) 2020-09-09 — — EP disclosed
US-10653795-B2 — — 2020-05-19 — — US disclosed
EP-2741779-A1 HIGH-LOADING WATER-SOLUBLE CARRIER-LINKED PRODRUGS Ascendis Pharma A/S (DK) 2014-06-18 — — EP disclosed
EP-2741778-A1 POLYMERIC HYPERBRANCHED CARRIER-LINKED PRODRUGS Ascendis Pharma A/S (DK) 2014-06-18 — — EP disclosed
US-20130053301-A1 DIPEPTIDE-BASED PRODRUG LINKERS FOR ALIPHATIC AMINE-CONTAINING DRUGS ASCENDIS PHARMA A/S (DK) 2013-02-28 — — US disclosed
WO-2013024048-A1 POLYMERIC HYPERBRANCHED CARRIER-LINKED PRODRUGS ASCENDIS PHARMA A/S (DK) 2013-02-21 — — WO disclosed
WO-2013024049-A1 PROTEIN CARRIER-LINKED PRODRUGS ASCENDIS PHARMA A/S (DK) 2013-02-21 — — WO disclosed
WO-2013024047-A1 HIGH-LOADING WATER-SOLUBLE CARRIER-LINKED PRODRUGS ASCENDIS PHARMA A/S (DK) 2013-02-21 — — WO disclosed
US-20120156259-A1 Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels ASCENDIS PHARMA A/S (DK) 2012-06-21 — — US disclosed
EP-2459220-A1 BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS Ascendis Pharma A/S (DK) 2012-06-06 — — EP disclosed
WO-2011089216-A1 DIPEPTIDE-BASED PRODRUG LINKERS FOR ALIPHATIC AMINE-CONTAINING DRUGS ASCENDIS PHARMA AS (DK) 2011-07-28 — — WO disclosed
WO-2011012715-A1 BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS ASCENDIS PHARMA AS (DK) 2011-02-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120156259-A1 Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels PLG, PHYKPL, PLOD3 PNP 1485/4885HBB 3696/4885BLM 595/4885
US-20130053301-A1 DIPEPTIDE-BASED PRODRUG LINKERS FOR ALIPHATIC AMINE-CONTAINING DRUGS DNPEP, PEPD, DAO PNP 756/4885HBB 3855/4885BLM 3105/4885
US-20230123784-A1 Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels PLG, PHYKPL, PLOD3 PNP 1485/4885HBB 3696/4885BLM 595/4885
US-20230381323-A1 RELEASABLE CONJUGATES GUSB, ABCB11, UGT2B7 PNP 913/4885HBB 1646/4885BLM 811/4885
US-10653795-B2 — PTMS, MSN, CD44 PNP 220/4885HBB 2591/4885BLM 967/4885
US-11559482-B2 Biodegradable polyethylene glycol based water-insoluble hydrogels PLG, PHYKPL, PLOD3 PNP 1485/4885HBB 3696/4885BLM 595/4885
US-11786599-B2 Releasable conjugates GUSB, ABCB11, UGT2B7 PNP 913/4885HBB 1646/4885BLM 811/4885
US-11116849-B2 Hydrogel-linked prodrugs releasing tagged drugs PTMS, PGLS, PAM PNP 257/4885HBB 1871/4885BLM 830/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.